| |
| Magyar Dermatológiai Társulat |
|
| 8. EADV Spring Symposium |
 Rendezvény kezdete: 2011.04.14. | Rendezvény vége: 2011.04.17. |
| Helyszín: Csehország, 360 01 Karlovy Vary (Carlsbad), I.P.Pavlova 11, Lazenský hotel THERMAL |
| A rendezvény Web oldala: http://www.eadvcarlsbad2011.org/ |
Important Dates:
Abstract submission deadline - 31 October, 2010
Abstract evaluation deadline - 17 January, 2011
Invited Speakers - Abstract submission deadline - 31 January, 2011
Early bird registration - 14 January, 2011
Hotel reservation deadline - 28 February, 2011
Opening of the Symposium - 14 April, 2011
Language
All presentations during the congress will be conducted in English, the official language of the EADV. There will be no translation provided.
|
|
|
 |
| |
| Magyar Endokrinológiai és Anyagcsere Társaság |
|
| XIV CAPRI CONFERENCE "Novel Mechanisms and clinical aspects of cardiovascular disorders |
| Rendezvény kezdete: 2011.04.15. | Rendezvény vége: 2011.04.17. |
| Szakterület(ek): Hipertónia, Kardiológia |
| Tudományos információ: Aristea International |
| Címe: Italy, 00198 Roma, Via Lima, 31 |
| Tel: +39 06 845431 |
| Fax: +39 06 84543700 |
| E-mail: roma@aristea.com |
| Szervező: Aristea International |
| Munkahely neve: Aristea |
| Címe: Italy, 00198 Roma, Via Lima, 31 |
| Tel: +39 06 845431 |
| Fax: +39 06 84543700 |
| E-mail: roma@aristea.com |
| Helyszín: www.capriconference.org, XIV CAPRI CONFERENCE "Novel Mechanisms and clinical aspects of cardiovascular disorders" |
The Capri Conference is an established and an international event where join together to develop and deal with the multiple and different discoveries that surround the Cardiovascular world.
This year our invited experts will discuss on various issues: from the management of Thromboembolism to the Atrial fibrillation, from new Antiplatelet Agents to Genetic aspects of Cardiomyopathies and to the latest guide line for the treatment of hypertension, heart and kidney.
The following are some of the Hot Topics:
• RAAS and metabolic syndrome
• Antialdosteronic therapy
• Lipids and cv events in the year 2011 – Residual risk
• New advances in the knowledge of renin
• Prevention/protection of MAU in hypertension
• BP targets in hypertension
• RAS and plaque stability
• RAS and vascular remodeling
• AT2 receptor agonists
• Prevention of CV disease in diabetes
• Prorenin/renin receptors
|
|
|
|
